Literature DB >> 28564620

Survivin in autoimmune diseases.

G Gravina1, C Wasén2, M J Garcia-Bonete3, M Turkkila4, M C Erlandsson5, S Töyrä Silfverswärd6, M Brisslert7, R Pullerits8, K M Andersson9, G Katona10, M I Bokarewa11.   

Abstract

Survivin is a protein functionally important for cell division, apoptosis, and possibly, for micro-RNA biogenesis. It is an established marker of malignant cell transformation. In non-malignant conditions, the unique properties of survivin make it indispensable for homeostasis of the immune system. Indeed, it is required for the innate and adaptive immune responses, controlling differentiation and maintenance of CD4+ and CD8+ memory T-cells, and in B cell maturation. Recently, survivin has emerged as an important player in the pathogenesis of autoimmune diseases. Under the conditions of unreserved inflammation, survivin enhances antigen presentation, maintains persistence of autoreactive cells, and supports production of autoantibodies. In this context, survivin takes its place as a diagnostic and prognostic marker in rheumatoid arthritis, psoriasis, systemic sclerosis and pulmonary arterial hypertension, neuropathology and multiple sclerosis, inflammatory bowel diseases and oral lichen planus. In this review, we summarise the knowledge about non-malignant properties of survivin and focus on its engagement in cellular and molecular pathology of autoimmune diseases. The review highlights utility of survivin measures for clinical applications. It provides rational for the survivin inhibiting strategies and presents results of recent reports on survivin inhibition in modern therapies of cancers and autoimmune diseases.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Hypoxia; Inflammation; Smoking; Survivin; Therapy

Mesh:

Substances:

Year:  2017        PMID: 28564620     DOI: 10.1016/j.autrev.2017.05.016

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  20 in total

1.  Cigarette smoking and risk of primary systemic vasculitis: a propensity score matching analysis.

Authors:  Alireza Khabbazi; Babak Alinejati; Mehrzad Hajialilo; Morteza Ghojazadeh; Aida Malek Mahdavi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

2.  Nonsurgical periodontal therapy decreases the severity of rheumatoid arthritis and the plasmatic and salivary levels of RANKL and Survivin: a short-term clinical study.

Authors:  Marcela Faria Moura; Tarcília Aparecida Silva; Luís Otávio Miranda Cota; Sicilia Rezende Oliveira; Fernando Queiroz Cunha; Gilda Aparecida Ferreira; José Roberto Cortelli; Sheila Cavalca Cortelli; Fernando Oliveira Costa
Journal:  Clin Oral Investig       Date:  2021-05-05       Impact factor: 3.573

Review 3.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

4.  Survivin Impairs the Apoptotic Machinery in CD4+ T Cells of Patients with Ulcerative Colitis.

Authors:  Bai-Sui Feng; Na Ma; Yuan-Yi Zhang; Han Gao; Cui Zhang; Gengfeng Li; Zhanju Liu; Yisheng Feng; Hai-Qiong Yu; Liang Xiao; Zhi-Gang Liu; Ping-Chang Yang
Journal:  J Innate Immun       Date:  2019-07-22       Impact factor: 7.349

Review 5.  Risk Factors from Pregnancy to Adulthood in Multiple Sclerosis Outcome.

Authors:  Enrique González-Madrid; Ma Andreina Rangel-Ramírez; María José Mendoza-León; Oscar Álvarez-Mardones; Pablo A González; Alexis M Kalergis; Ma Cecilia Opazo; Claudia A Riedel
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

6.  The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model.

Authors:  Xiangyang Zhang; Michael Ciesielski; Robert A Fenstermaker; Henry J Kaminski; Linda L Kusner
Journal:  J Immunol       Date:  2020-08-24       Impact factor: 5.422

Review 7.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

8.  Circulating Survivin Levels in Obstructive Sleep Apnoea.

Authors:  Laszlo Kunos; Peter Horvath; Adrian Kis; David Laszlo Tarnoki; Adam Domonkos Tarnoki; Zsofia Lazar; Andras Bikov
Journal:  Lung       Date:  2018-05-08       Impact factor: 2.584

9.  Modulation of microRNome by Human Cytomegalovirus and Human Herpesvirus 6 Infection in Human Dermal Fibroblasts: Possible Significance in the Induction of Fibrosis in Systemic Sclerosis.

Authors:  Irene Soffritti; Maria D'Accolti; Gloria Ravegnini; Maria-Cristina Arcangeletti; Clara Maccari; Flora De Conto; Adriana Calderaro; Elisabetta Caselli
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

10.  Survivin Measurement improves Clinical Prediction of Transition From Arthralgia to RA-Biomarkers to Improve Clinical Sensitivity of Transition From Arthralgia to RA.

Authors:  Malin C Erlandsson; Minna Turkkila; Rille Pullerits; Maria I Bokarewa
Journal:  Front Med (Lausanne)       Date:  2018-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.